• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Alterity Therapeutics Limited - American Depositary Shares (NQ:ATHE)

    4.030 -0.640 (-13.70%)
    Streaming Delayed Price Updated: 3:53 PM EDT, May 15, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 76,550
    Open 4.450
    Bid (Size) 4.010 (1,000)
    Ask (Size) 4.050 (100)
    Prev. Close 4.670
    Today's Range 3.840 - 4.480
    52wk Range 2.660 - 7.000
    Shares Outstanding 2,084,016,678
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire

    Performance

    YTD
    +27.5%
    +27.5%
    1 Month
    +11.3%
    +11.3%
    3 Month
    +14.8%
    +14.8%
    6 Month
    +9.2%
    +9.2%
    1 Year
    -1.7%
    -1.7%

    More News

    Read More
    News headline image
    Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics: Appendix 4C – Q1 FY26 Quarterly Cash Flow Report
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Thursday's after hours session: top gainers and losers ↗
    Via Chartmill
    News headline image
    Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Presents ATH434-201 Phase 2 Data at the American Neurological Association Annual Meeting
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics Raises A$20.0 million in Strategic Placement
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire
    News headline image
    Alterity Therapeutics to Present at the Biotech Showcase
    From ALTERITY THERAPEUTICS LIMITED
    Via GlobeNewswire

    Frequently Asked Questions

    Is Alterity Therapeutics Limited - American Depositary Shares publicly traded?
    Yes, Alterity Therapeutics Limited - American Depositary Shares is publicly traded.
    What exchange does Alterity Therapeutics Limited - American Depositary Shares trade on?
    Alterity Therapeutics Limited - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Alterity Therapeutics Limited - American Depositary Shares?
    The ticker symbol for Alterity Therapeutics Limited - American Depositary Shares is ATHE on the Nasdaq Stock Market
    What is the current price of Alterity Therapeutics Limited - American Depositary Shares?
    The current price of Alterity Therapeutics Limited - American Depositary Shares is 4.030
    When was Alterity Therapeutics Limited - American Depositary Shares last traded?
    The last trade of Alterity Therapeutics Limited - American Depositary Shares was at 05/15/26 03:53 PM ET
    What is the market capitalization of Alterity Therapeutics Limited - American Depositary Shares?
    The market capitalization of Alterity Therapeutics Limited - American Depositary Shares is 8.40B
    How many shares of Alterity Therapeutics Limited - American Depositary Shares are outstanding?
    Alterity Therapeutics Limited - American Depositary Shares has 8B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.